Women with a *BRCA1* or *BRCA2* mutation have limited choices to prevent mortality resulting from their 40--80% lifetime risk for breast cancer ([@bib2]). Screening with yearly MRI from age 25 years onwards, and additional mammography from age 30 years is recommended in international guidelines ([@bib17]; [@bib28]; [@bib36]; [@bib19]), and is estimated to be slightly less effective than preventive mastectomy ([@bib12]; [@bib6]). Several prospective high-risk screening studies have evaluated both MRI and mammography ([@bib16]; [@bib34]) as a screening strategy in high-risk women to improve screening sensitivity. In the absence of randomised controlled trials for MRI screening, these screening studies build on evidence that early detection of breast cancer may confer benefit as shown for mammography in population screening ([@bib4]). The combination of mammography and MRI screening of *BRCA1/2* carriers in most guidelines, from the age of 30 or 40 years ([@bib17]; [@bib28]; [@bib36]; [@bib19]), is based on the enhanced sensitivity shown through this strategy ([@bib16]; [@bib34]), despite arguments around limitations of mammography. These include that mammography is relatively sensitive in fatty breasts (generally in older women) but less sensitive in young women who frequently have dense breasts. In addition, screening with mammography could lead to the induction of breast cancer by X-rays at younger ages ([@bib9]). Proper repair of DNA double-strand breaks that are caused by low-dose X-rays is impaired at any age in both *BRCA1* and *BRCA2* mutations carriers ([@bib25]). This makes *BRCA1* and *BRCA2* mutation carriers more susceptible than non-carriers, possibly also at older ages, to the cumulative effect of yearly mammograms. Given these potential disadvantages of mammography, it is important to balance the potential benefits and harms of mammography screening in *BRCA1/2* mutation carriers. Hence, substantial early detection of breast cancer by mammography is needed to outweigh the potential harm of cancer induction ([@bib9]) in *BRCA1/2* mutation carriers.

We performed an individual patient data (IPD) meta-analysis from six prospective MRI screening studies to determine if mammography screening in *BRCA1/2* mutation carriers in addition to MRI improves screening accuracy, and whether this effect differs between *BRCA1* and *BRCA2* gene mutation carriers or by different age groups.

Materials and methods
=====================

An IPD meta-analysis was conducted by pooling individual data from relevant prospective MRI screening studies ([@bib22]). Studies were eligible if mammography and MRI breast cancer sensitivity and specificity were compared in women with a *BRCA1/2* mutation. After searching PubMed, 12 studies met the eligibility requirements and were sought to contribute to the data ([@bib22]). Six of these provided IPD data ([@bib13]; [@bib27]; [@bib32]; [@bib29]; [@bib21]; [@bib26]), and were included in this meta-analysis; the reasons for non-inclusion of some studies have been reported in our earlier work ([@bib22]). Included studies were assessed in terms of reporting quality, and were qualified as high quality ([@bib22]). The data were assembled and cross-checked with the original publications; inclusion criteria for analyses were women with a *BRCA1/2* mutation, screened annually with both mammography and MRI. Breast cancer diagnosis was confirmed by pathology and the absence of breast cancer at 1 year follow-up ([@bib22]). A summary of the included studies was reported previously (<http://jco.ascopubs.org/content/33/4/349/T1.large.jpg>)

Primary outcome and definition
------------------------------

Primary outcome was sensitivity and specificity of mammography and MRI separately, as well as combined. Analyses were stratified for mutation type (*BRCA1* or *BRCA2*) and age in years at screening (40 years and younger, between 41 and 50 years, over 50 years).

Sensitivity was defined as the number of breast cancers detected by a screening modality (MRI or mammography, or the combination) from the total number of breast cancers diagnosed during the study course. Specificity of a screening modality was defined as the number classified as true negative by the test from the total number of true-negative plus false-positive results.

A true positive was defined as a positive screening result (BI-RADS 0, 3, 4, 5) followed by a pathology-proven breast cancer. A false positive was defined as a positive screening result (BI-RADS 0, 3, 4, 5) not followed by a pathology-proven breast cancer within 1 year of follow-up. A true negative was defined as a negative screening result (BI-RADS 1, 2) not followed by pathology-proven breast cancer within 1 year of follow-up. A false-negative case was defined as a negative screening result (BI-RADS 1, 2) followed by a pathology-proven breast cancer within 1 year of follow-up.

Statistical analysis
--------------------

Stratified by *BRCA* status and age group, descriptive statistics of the characteristics of the women and their breast cancer were provided. Breast cancer incidence was calculated per 1000 woman-years. The related 95% confidence intervals (CIs) were computed, assuming the incidence follows a Poisson distribution. To compare differences between groups in proportion of DCIS, invasive tumour size and grade, *χ*^2^ tests or Fisher\'s exact tests were applied.

To estimate the sensitivity and the specificity of the screening modalities, repeated screening results were summarised to form binomial counts for each woman. For each woman, the number of true-positive and true-negative screens per modality, and the number of total screening visits with or without breast cancer detected were counted. In this way, binomial counts per modality were calculated and analysed, taking into account that each woman was her own control. As the dependent variable was assumed to follow a binomial distribution, a generalised linear mixed model with logit link function was applied, and the binomial proportions were modelled as a function of modality and *BRCA* status and conducted separately for sensitivity and specificity. Studies were entered as random-effect variables and study heterogeneities were assumed to depend on modality. The analyses were conducted separately for each age group. To test the differences between the sensitivities and specificities for the three modalities, Wald tests were applied, where the hypothesis was that the difference between the two proportions under study was 0.

The number of mammographic screens that would have been needed (NSN) to detect one breast cancer that was missed by MRI was calculated, and stratified according to BRCA mutation, age group and screening round (first or subsequent round). All analyses were performed using SAS 9.4 (SAS Institute, Cary, NC, USA). *P*-values \<0.05 were considered statistically significant.

Results
=======

Study population and breast cancer characteristic
-------------------------------------------------

The analyses were based on 1951 *BRCA1/2* mutation carriers with 6085 woman-years of follow-up ([Table 1](#tbl1){ref-type="table"}). There was no significant difference in cancer risk between *BRCA1* and *BRCA2* mutation carriers.

Five breast cancers were diagnosed before the age of 30 in *BRCA1* mutation carriers, and none in *BRCA2* mutation carriers. The proportion of DCIS differed between BRCA groups in age groups older than 40 years, as shown in [Table 1](#tbl1){ref-type="table"}.

Sensitivity and specificity of MRI and mammography in BRCA1 mutation carriers
-----------------------------------------------------------------------------

In *BRCA1* mutation carriers, there were no statistically significant differences in sensitivity and specificity between mammography and MRI combined compared with MRI alone. Sensitivity of the combination was higher compared with that of MRI alone in all age groups (age ⩽40: 86.8% (63.1--96.2) *vs* 77.5% (57--90), *P*=0.441; age 41--50: 94.1% (74.5--98.9) *vs* 93.1% (70.8--98.7), *P*=0.895; age \>50: 89.3% (71.3--96.6) *vs* 89.1% (54.8--98.2), *P*=0.986). Combining mammography and MRI decreased specificity compared with MRI screening alone in all age groups (age ⩽40 years: 81% (73.9--86.5) *vs* 84.3% (78.7--88.7), *P*=0.409; age 41--50 years: 77.2% (70.5--82.8) *vs* 82.9% (77.9--87), *P*=0.135; age \>50 years: 87.4% (79.3--92.6) *vs* 89.9% (82.6--94.3), *P*=0.566). Further results are shown in [Table 2](#tbl2){ref-type="table"}.

Sensitivity and specificity of MRI and mammography in *BRCA2* mutation carriers
-------------------------------------------------------------------------------

In *BRCA2* carriers, there were no significant differences in sensitivity or specificity between combined mammography and MRI and MRI alone in all age groups. Sensitivity of the combination was higher compared with that of MRI alone in all age groups (age ⩽40 years: 87.2% (56.1--97.3) *vs* 52.7% (27.2--76.8), *P*=0.075; age 41--50 years: 91.2% (70.4--97.9) *vs* 86.4% (58.2--96.7), *P*=0.646; age \>50 years: 94.1% (67.5--99.2) *vs* 85% (43.7--97.7), *P*=0.474). Combining mammography and MRI decreased specificity compared with MRI screening alone in all age groups (age ⩽40 years: 75.3% (66.6--82.4) *vs* 80.2% (72.9--85.8), *P*=0.351; age 41--50 years: 80% (73.3--85.3) *vs* 86% (81.1--89.8), *P*=0.105; age \>50 years: 88.6% (80.7--93.6) *vs* 91.1% (84--95.2), *P*=0.565). Further results are shown in [Table 2](#tbl2){ref-type="table"}.

Mammography contribution to screening sensitivity in *BRCA1* mutation carriers
------------------------------------------------------------------------------

In *BRCA1* carriers overall, adding mammography to MRI screening increased sensitivity by roughly 4--92.5% ([Table 2](#tbl2){ref-type="table"}) (*P*=0.553). In the ⩽40 years age group, the addition of mammography increased sensitivity by 9.3% ([Table 2](#tbl2){ref-type="table"}). Without mammography, 3 of 46 (6.5%) breast cancers, including 2 DCIS, would not have been detected ([Table 3](#tbl3){ref-type="table"}) in this subgroup. In the 41--50 years group, additional mammography increased sensitivity by only 1% ([Table 2](#tbl2){ref-type="table"}), detecting 1 DCIS (2.7%) ([Table 3](#tbl3){ref-type="table"}). Similarly, in the \>50 years age group, mammography detected one additional cancer (3.4% of cancers) ([Table 3](#tbl3){ref-type="table"}).

Mammography contribution to screening sensitivity in *BRCA2* mutation carriers
------------------------------------------------------------------------------

In *BRCA2* carriers, adding mammography to MRI screening increased sensitivity by 12.6--92.7% ([Table 2](#tbl2){ref-type="table"}) (*P*=0.154). In the ⩽40 age group, additional mammography increased sensitivity by 34.5% ([Table 2](#tbl2){ref-type="table"}). Without mammography, 6 of 18 cancers (33.3%), including 2 DCIS, would not have been detected in this young age group ([Table 3](#tbl3){ref-type="table"}). In women aged 41--50 years, adding mammography nonsignificantly increased sensitivity by nearly 5% ([Table 2](#tbl2){ref-type="table"}) and detected 3 cancers, including 1 DCIS, which were not detected by MRI (8.1% of cancers). In the \>50 years age group, screening sensitivity increased nonsignificantly by ∼9% ([Table 2](#tbl2){ref-type="table"}), and mammography detected two cancers (11.8%) that were not detected by MRI, including 1 DCIS.

Number of mammographic screens needed to detect one breast cancer not detected by MRI
-------------------------------------------------------------------------------------

For the first screening round, the NSN for mammography to detect one breast cancer not detected by MRI was 527 for women with a *BRCA1* mutation and 94 for women with a *BRCA2* mutation for all ages ([Table 4](#tbl4){ref-type="table"}). For subsequent screening rounds, the NSN for mammography to detect an additional breast cancer for women with a *BRCA1* mutation (717 screens) was roughly three times that for women with a *BRCA2* mutation (231 screens).

Discussion
==========

This IPD meta-analysis has identified differences in the contribution of mammography to screening high-risk women according to age and mutation status. Adding mammography to MRI screening in *BRCA1* mutation carriers leads to a very modest increase in sensitivity of 3.9% among 112 breast cancers (*P*=0.553), and a small decrease in specificity (by 4%, *P*=0.154). One invasive cancer and 2 DCIS (6.5%) of the 46 *BRCA1* breast cancers detected before the age of 40 years, and only 1 DCIS and 1 invasive cancer \<1 cm (3%) in a total of 66 *BRCA1* breast cancers would not have been detected at that screen after the age of 40 years. The percentage of early-stage (DCIS or \<1 cm invasive) cancers detected with both MRI and mammography screening of 36.6% (41 out of 112) would decrease by 3.6% (37 out of 112) if mammography was not be performed. Using combined MRI and mammography, 63.4% of the detected cancers were invasive and \>1 cm, with 0.9% of these detected by mammography only. To detect one breast cancer missed by MRI, we estimated that 527 screens for the first screening round and 717 screens for subsequent rounds with mammography would be needed.

The contribution of mammography above MRI to screening sensitivity in the 72 *BRCA2* mutation carriers was 12.6% (*P*\>0.05). Additional mammography in *BRCA2* mutation carriers also decreased the specificity. Without mammography one-third of breast cancers would not have been detected in *BRCA2* mutation carriers aged 40 years and younger, but this proportion was 9.3% in those older than 40 years. We estimate that the percentage of *BRCA2* cancers detected at very early stage (DCIS or invasive \<1 cm) with combined MRI and mammography screening of 54.2% (39 out of 72) would decrease to 47.2% (34 out of 72) without mammography. Only 94 screens at first round and 231 screens at subsequent rounds of mammography screening are needed to detect a breast cancer missed by MRI. Without mammography, four advanced-stage cancers (4 out of 72 cancers, 5.6%) would have been missed in *BRCA2* carriers. An advantage of mammography over MRI has been the ability to detect DCIS by visualising microcalcifications. The proportion of DCIS is larger for women with a *BRCA2* mutation than for women with a *BRCA1* mutation, thus differences in histology distributions in *BRCA*-associated breast cancers may account for our findings ([@bib7]). There might also be *BRCA* mutation-specific differences in tumour phenotypes that also contribute to differences in screen detection. The modest additional value of digital-only mammography to current MRI screening of *BRCA1* mutation carriers was recently shown in a retrospective study ([@bib20]). Only 2 (2%) DCIS of 94 breast cancers were detected by mammography alone, none in women aged below 40 years and no invasive cancers. Importantly, in this retrospective study with recent data MRI screening detected 67% of the breast cancers detected as DCIS or \<1 cm, considerably more than the 41--44% published for the Dutch, UK and Canadian studies of our IPD meta-analyses ([@bib27]; [@bib21]; [@bib3]) or 36.6% of this IPD meta-analysis.

It could be argued that at the time the studies forming our IPD analyses were conducted, radiologists might not have had extensive experience with breast MRI screening. Most likely, both a learning curve, as expected for any new screening modality, and improved techniques explain the relatively improved MRI sensitivities in more recent studies. A learning curve for MRI screening accuracy in high-risk women was evident for the Canadian study, in particular for DCIS detection ([@bib33]). However, in a previous report in this study population ([@bib22]), the sensitivity of each of MRI and mammography fluctuated over the years, and heterogeneity was evident across different studies possibly masking any potential effect of timeframe ([@bib22]). A cohort study from the Netherlands showed that digital mammography had higher sensitivity compared with studies reporting film mammography (and a transition to digital) ([@bib20]). However, in the Italian HIBCRIT-1 Study, transition from film screen to digital mammography (resulting in screening with roughly equal mix of film screen and digital) did not increase mammography sensitivity in high-risk women ([@bib29]). Newer mammography technologies such as tomosynthesis (3D mammography), which have better screening sensitivity than standard mammography ([@bib8]), have not yet been compared with MRI screening of *BRCA* carriers. This lacking evidence in high-risk screening is worthy of research effort but would still imply increased ionising radiation from tomosynthesis ([@bib30]).

In contrast to benefits of possible earlier breast cancer detection, there are also possible harmful effects of additional mammography as outlined in the Introduction. Two-fold increase in breast cancers in *BRCA1/2* mutation carriers after exposure to 4 or more radiographs, compared with non-exposure, was significant below age 30 years (HR=1.9 (95% CI: 1.2--3.0), but not at 30--39 years ([@bib24]). Two other studies did not demonstrate tumour induction in *BRCA1/2* mutation carriers by screening mammography or low-dose contralateral irradiation from breast-conserving treatment ([@bib23]; [@bib18]). However, this may have been because of modest follow-up time in these studies, with consideration that latency time for radiation-induced breast cancer is 10--15 years ([@bib31]; [@bib9]).

From two meta-analyses based on retrospective studies, the estimated cumulative risk of breast cancer by the age of 70 years vary from 57% (95% CI: 47--66%) to 65% (95% CI: 44--78) in women with a *BRCA1* mutation and from 45% (95% CI: 31--56%) to 49% (95% CI: 40--57) in women with a *BRCA2* mutation ([@bib1]; [@bib2]). In this IPD meta-analysis, we combined IPD from six prospective studies, making this the largest analysis in the world of prospectively collected screening data on *BRCA1/2* mutation carriers, although numbers are modest in some subgroups. We did not observe a significant difference in the risk of breast cancer between *BRCA1* and *BRCA2* mutation carriers given a relatively small sample of breast cancers in the IPD data set. Although data from six studies could not be included, this only resulted in ∼716 women with *BRCA1/2* mutations (36 breast cancers) not being included in the IPD ([@bib11], [@bib10]; [@bib14], [@bib15]; [@bib5]; [@bib35]). As these studies showed generally similar results for the added value of mammography to MRI, we would not expect their non-inclusion to have substantially altered our estimates.

This work differs from our recent report using the same IPD data ([@bib22]) because the present analyses focus on screening outcomes by *BRCA* status and age group to determine mammography\'s contribution. Based on our findings, the additional detection from mammography in *BRCA1* mutation carriers who receive MRI screening is minimal, and might not outweigh potential disadvantages (potential cancer induction by radiation, false-positive results). It may be reasonable, on the basis of this collective evidence, to consider potential omission of mammography screening in *BRCA1* mutation carriers or to open discussion on its potential omission given its limited contribution. In *BRCA2* mutation carriers, the contribution of mammography above MRI is more evident. Different screening recommendations for these two groups of women defined by *BRCA* mutation status should be considered on the basis of the evidence we report, factoring the estimated contribution of mammography and its potential harms.
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###### Overview of women (*n*=1951) and their BCs (*n*=184)[a](#t1-fn3){ref-type="fn"}

                                                   **All ages**     **Age ⩽40 years**    **Age 41**--**50 years**   **Age over 50 years**                                                              
  ---------------------------------------------- ----------------- -------------------- -------------------------- ----------------------- ------------------- ------------------- ------------------- -------------------
  Women (*N*)                                          1219                732                     605                       301                   482                 308                 310                 228
  Follow-up time (woman-years)                         3840                2245                    1691                      749                  1216                 812                 895                 673
  BC (*N*)                                              112                 72                      46                       18                    38                  37                  28                  17
  BC risk ((95% CI)                               29.2 (24--35.1)   32.1 (25.1--.40.4)      27.2 (19.9--36.3)           24 (14.2--38)       31.3 (22.1--42.9)   45.6 (32.1--62.8)   31.3 (20.8--45.2)   25.3 (14.7--40.4)
  DCIS[b](#t1-fn4){ref-type="fn"}                   15 (13.4%)          22 (30.6%)              9 (19.6%)                 3 (16.7%)             3 (7.9%)           13 (35.1%)           3 (10.7%)           6 (35.3%)
  Invasive cancers[c](#t1-fn5){ref-type="fn"}       97 (86.6%)          50 (69.4%)              37 (80.4%)               15 (83.3%)            35 (92.1%)          24 (64.9%)          25 (89.3%)          11 (64.7%)
  Invasive \<1 cm                                   26 (26.8%)          17 (34.0%)              8 (21.6%)                 2 (13.3%)            10 (28.6%)          11 (45.8%)           8 (32.0%)           4 (36.4%)
  Invasive 1--2 cm                                  35 (36.1%)          12 (24.0%)              13 (35.1%)                5 (33.3%)             8 (22.9%)           3 (12.5%)          14 (56.0%)           4 (36.4%)
  Grade 1                                            7 (7.2%)           5 (10.0%)                1 (2.7%)                   0 (−)               4 (11.4%)           3 (12.5%)           2 (8.0%)            2 (18.2%)
  Early-stage tumour (DCIS or invasive \<1 cm)       41(36.6%)          39 (54.2%)              17 (37.0%)                5 (27.8%)            13 (34.2%)          24 (64.9%)          11 (39.3%)          10 (58.8%)

Abbreviations: BC=breast cancer; DCIS=ductal carcinoma *in situ*.

BC risk was expressed per 1000 woman-years of follow-up.

Stratified by age at screening and for *BRCA1* or *BRCA2* mutation status

*P*=0.0095 comparing DCIS rate between *BRCA1* and *BRCA2* mutation carriers at the age 41--50 years, and for all ages, comparing DCIS rate between *BRCA1* and *BRCA2* mutation carriers, *P*=0.0077.

Nine cases with missing histological subtype were considered as invasive BCs.

###### Sensitivity and specificity of screening modalities[a](#t2-fn2){ref-type="fn"}

                               **Mammography**   **MRI**             **Combination**                                                                           
  ---------- ----------------- ----------------- ------------------- ------------------- ---- ------------------- ------------------- ---- ------------------- -------------------
  All ages   *BRCA1* (n=112)   39                35.7 (25.9--46.9)   93.8 (89.3--96.5)   92   88.6 (73.4--95.6)   84.4 (78.7--88.8)   98   92.5 (80.1--97.4)   80.4 (72.8--86.2)
             *BRCA2* (n=72)    31                44.6 (31.9--58)     93.4 (88.4--96.3)   53   80.1 (58.9--91.9)   85.3 (79.6--89.6)   64   92.7 (79.3--97.7)   80.5 (72.8--86.4)
  ⩽40        *BRCA1* (n=46)    18                39.1 (26.2--53.9)   94.9 (91.2--97.1)   34   77.5 (57--90)       84.3 (78.7--88.7)   38   86.8 (63.1--96.2)   81 (73.9--86.5)
             *BRCA2* (n=18)    10                55.6 (32.9--76.1)   92.3 (86.6--95.7)   9    52.7 (27.2--76.8)   80.2 (72.9--85.8)   15   87.2 (56.1--97.3)   75.3 (66.6--82.4)
  41--50     *BRCA1* (n=38)    13                34.2 (21--50.5)     91.5 (86.7--94.6)   34   93.1 (70.8--98.7)   82.9 (77.9--87)     35   94.1 (74.5--98.9)   77.2 (70.5--82.8)
             *BRCA2* (n=38)    14                37.8 (22.7--55.5)   92 (87--95.2)       30   86.4 (58.2--96.7)   86 (81.1--89.8)     33   91.2 (70.4--97.9)   80 (73.3--85.3)
  \>50       *BRCA1* (n=28)    8                 29.4 (12.8--54.2)   96.8 (91.9--98.8)   24   89.1 (54.8--98.2)   89.9 (82.6--94.3)   25   89.3 (71.3--96.6)   87.4 (79.3--92.6)
             *BRCA2* (n=17)    7                 45.5 (19.3--74.4)   97.4(92.8--99.1)    14   85 (43.7--97.7)     91.1 (84--95.2)     16   94.1 (67.5--99.2)   88.6 (80.7--93.6)

Abbreviations: BC=breast cancer; CI=confidence interval; MRI=magnetic resonance imaging.

Stratified by age at screening and by *BRCA1* or *BRCA2* mutation status.

###### Mammography-only detected breast cancers stratified for *BRCA1* or *BRCA2* mutation status

  **No.**    **Mutation status**  **Age at diagnosis**    **Tumour type**   **Invasive tumour size**   **Invasive tumour grade**  **Screening round**
  --------- --------------------- ---------------------- ----------------- -------------------------- --------------------------- ---------------------
  1                *BRCA1*        31                           DCIS                   ---                         ---             2
  2                *BRCA1*        33                           DCIS                   ---                         ---             2
  3                *BRCA1*        40                            IDC                 1--2 cm                     Grade 3           1
  4                *BRCA1*        42                           DCIS                   ---                         ---             3
  5                *BRCA1*        56                            IDC                  \<1 cm                     Grade 3           4
  1                *BRCA2*        36                           DCIS                   ---                         ---             1
  2                *BRCA2*        37                           DCIS                   ---                         ---             1
  3                *BRCA2*        35                            IDC                  \<1 cm                     Grade 2           4
  4                *BRCA2*        36                            IDC                 1--2 cm                     Grade 3           1
  5                *BRCA2*        37                            ILC                 2--5 cm                     Grade 2           1
  6                *BRCA2*        39                           Other                   NA                         NA              3
  7                *BRCA2*        42                           DCIS                   ---                         ---             4
  8                *BRCA2*        53                           DCIS                   ---                         ---             2
  9                *BRCA2*        44                            ILC                  \>5 cm                        3              1
  10               *BRCA2*        47                            ILC                  \>5 cm                        2              5
  11               *BRCA2*        51                            NA                     NA                         NA              1

Abbreviations: DCIS=ductal carcinoma *in situ*; IDC=invasive ductal; ILC=invasive lobular; NA=not applicable.

###### NSN for one additional mammography-only detected cancer for first and subsequent screening rounds

  ***BRCA***                                 **Age group (years)**   **Number of BC in study subjects**   **Number of screens**   **BC only detected by mammography**   **NSN for mammography to detect one BC missed by MRI**
  ------------------------------------------ ----------------------- ------------------------------------ ----------------------- ------------------------------------- --------------------------------------------------------
  **First screening round**                                                                                                                                             
  *BRCA1*                                    All ages                45                                   1053                    2                                     527
                                             Age \<40                19                                   555                     2                                     278
                                             41--50                  14                                   304                     0                                     NA
                                             Age \>50                12                                   194                     0                                     NA
  *BRCA2*                                    All ages                18                                   564                     6                                     94
                                             Age \<40                10                                   221                     4                                     55
                                             41--50                  10                                   204                     1                                     204
                                             Age \>50                8                                    139                     1                                     139
  **Subsequent (repeat) screening rounds**                                                                                                                              
  *BRCA1*                                    All ages                67                                   2150                    3                                     717
                                             Age \<40                27                                   775                     1                                     775
                                             41--50                  23                                   797                     1                                     797
                                             Age \>50                17                                   578                     1                                     578
  *BRCA2*                                    All ages                54                                   1155                    5                                     231
                                             Age \<40                8                                    281                     2                                     141
                                             41--50                  27                                   444                     2                                     222
                                             Age \>50                9                                    430                     1                                     430

Abbreviations: BC=breast cancer; MRI=magnetic resonance imaging; NA=not applicable; NSN=number of screens needed.
